THE PROBLEM

Half the world’s adult population has metabolic syndrome or its downstream conditions

Quite likely either you or someone you know has metabolic syndrome or its downstream conditions...

Current treatments are imprecise "one-size-fits-all" medicines

A PILOT FOR PRECISION MEDICINE IN METABOLIC SYNDROME

Success of cancer precision medicines indicates what’s possible in metabolic syndrome-conditions

PRECISION THERAPEUTICS FOCUS THE RIGHT TREATMENT ON THE RIGHT PATIENT

The Market Potential

The oncology drugs market has grown from $10 billion in 2000 to over $140 billion in 2019​

Estimated world metabolic syndrome drug market in 2040 after precision revolution is >$1.6 trillion

THE NEED FOR MULTIPLE OMICS

Metabolic syndrome-related conditions are multifactorial, requiring more complex data to unravel

METABOLIC SYNDROME DISEASE ORIGIN AND PROGRESSION ARE INFLUENCED BY MANY FACTORS BESIDES THE GENOME AND ALSO THEIR UNIQUE INTERACTIONS WITH ONE ANOTHER

WHAT WE ARE BUILDING

THE MOHSAIC® PLATFORM

1

MultiOmic’s process begins with the collection of biological samples along with clinical and outcome data

2

Multi-omics data is derived from these samples

3

Raw data from the vendors is pooled into a central data lake

4

The data lake is used to build artificial intelligence (AI)-enabled computational system biology models that are fine-tuned with wet lab experimentation

5

The model is utilized to identify endotypes, causal pathways and precision therapeutics

Data-DRIVEN THERAPEUTICS FOR WORLD'S #1 HEALTH PROBLEM